Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation
From General Health Surveillance to Pharmaceutical Safety
For decades, the general health and science information landscape has served as a foundational archive for understanding broad environmental and pharmaceutical influences on human well-being. This legacy, rooted in documenting the intersection of developmental medicine and patient advocacy, established rigorous standards for tracking how external factors—from environmental exposures to therapeutic interventions—interact with population health. The same methodological discipline that once catalogued pediatric neurological outcomes now provides a framework for examining emerging pharmaceutical safety questions in occupational contexts. As industrial production scales and therapeutic agents become more widely deployed, the transition from general health surveillance to specific exposure risk assessment becomes critical. The principles of documenting environmental health impacts, long applied to developmental conditions, naturally extend to evaluating how pharmaceutical compounds may affect workers in manufacturing settings. This pivot requires no mechanistic speculation, only a recognition that the same rigorous documentation standards apply when assessing potential occupational hazards. The archive’s evolution from pediatric neurology to pharmaceutical safety reflects a broader shift in public health inquiry: from passive observation of general population trends to active investigation of exposure scenarios in controlled production environments. This transition maintains the neutral, evidence-based approach that has always characterized responsible health communication, now focused on the specific question of occupational risk associated with therapeutic agents in mass production settings.
Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Etiology and Epidemiology
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/).
Avelumab and MCC: Therapeutic Relationship, Not Causation
The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but rather of therapeutic intervention. Avelumab is used to treat MCC, not to cause it. The evidence indicates that avelumab is an approved and effective treatment for metastatic MCC, with clinical trials demonstrating objective responses in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who are refractory to avelumab, alternative treatment options such as combined ipilimumab and nivolumab have been investigated. In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC patients, with three out of five patients responding to the combination according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further supports the use of this combination in patients who progress on avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Risk Context and Clinical Considerations
Regarding risk anchors, the adequacy of warnings about avelumab and MCC must be considered in the context of its approved use. The prescribing information for avelumab includes warnings about immune-related adverse events, which are common with immune checkpoint inhibitors. However, the evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. Causation-related considerations for affected patients would focus on the natural history of MCC and the role of avelumab as a therapeutic agent. The timeline between exposure to avelumab and documented harm would relate to the development of immune-related adverse events, which can occur during treatment, rather than the development of MCC itself. The evidence shows that avelumab is used to treat MCC, and for patients who do not respond or progress, alternative therapies are available (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the available evidence supports avelumab as an effective treatment for metastatic MCC, with a well-characterized mechanism of action as a PD-L1 inhibitor. There is no evidence to suggest that avelumab causes MCC; instead, it is a therapeutic option for patients with this aggressive skin cancer. The risk narrative should emphasize the clinical benefits and limitations of avelumab in MCC, including the potential for immune-related adverse events and the need for alternative treatments in refractory cases.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No. Avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC based on clinical trials showing objective responses in about one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/).
What is the mechanism of avelumab in Merkel cell carcinoma?
Avelumab targets PD-L1, blocking its interaction with PD-1, thereby reactivating T-cell antitumor immune responses. This mechanism is therapeutic, not causative (https://pubmed.ncbi.nlm.nih.gov/29799096/).
What are the main risk factors for Merkel cell carcinoma?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.